Paolo G. Casali
保罗·卡萨利
MD
Professor of Medical Oncology; Head, Adult Soft Tissue Sarcoma and Rare Tumors Unit
👥Biography 个人简介
Paolo G. Casali, MD is Professor of Medical Oncology and Head of the Adult Soft Tissue Sarcoma and Rare Tumors Unit at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan. He is one of the most influential figures in global sarcoma and rare cancer medicine, with decades of leadership in clinical trials, guidelines development, and the establishment of reference networks for rare cancers in Europe. He has been a lead author of ESMO Clinical Practice Guidelines for soft tissue sarcoma, GIST, and bone sarcoma—the most widely used clinical standards in these diseases worldwide. Dr. Casali co-led the first large-scale trials of imatinib in GIST and has participated as lead investigator in numerous landmark phase III studies of systemic therapy in sarcoma. He co-founded and co-directs the European Reference Network for Rare Adult Solid Cancers (EURACAN) and is a past president of CTOS. With over 500 peer-reviewed publications and an h-index exceeding 90, he is among the most cited sarcoma researchers in the world.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ESMO Clinical Practice Guidelines for Sarcoma and GIST
Lead author and co-author of the ESMO Clinical Practice Guidelines for soft tissue sarcoma, gastrointestinal stromal tumors, and bone sarcomas—regularly updated consensus documents that serve as the primary global reference for sarcoma treatment standards adopted by oncologists across more than 100 countries.
Imatinib in Advanced GIST: Pivotal European Trials
Served as a leading European investigator and co-author of the pivotal randomized trials of imatinib in advanced GIST, including the B2222 and EORTC phase II/III studies, contributing foundational evidence establishing imatinib as the paradigm-shifting treatment that defined molecularly targeted oncology.
EURACAN: European Reference Network for Rare Adult Cancers
Co-founded and directs EURACAN (European Reference Network for Rare Adult Solid Cancers), the EU-designated pan-European network connecting reference centers for rare adult cancers including sarcoma, enabling coordinated expert care, second-opinion infrastructure, and multinational clinical trials for rare mesenchymal malignancies.
Adjuvant Imatinib and Tailored Duration in Resected GIST
Contributed to landmark Scandinavian Sarcoma Group (SSGXVIII/AIO) and related trials demonstrating that 3 years of adjuvant imatinib significantly improved recurrence-free and overall survival compared to 1 year in patients with high-risk resected GIST, establishing 3 years as the standard adjuvant duration.
Representative Works 代表性著作
ESMO/European Sarcoma Network Working Group: Soft Tissue and Visceral Sarcomas — ESMO Clinical Practice Guidelines
Annals of Oncology (2022)
Comprehensive ESMO Clinical Practice Guidelines for soft tissue sarcomas providing evidence-based recommendations for staging, systemic therapy, and multidisciplinary management, representing the global reference standard.
Gastrointestinal Stromal Tumours: ESMO Clinical Practice Guidelines
Annals of Oncology (2022)
Lead-authored ESMO guidelines for GIST covering molecular testing, treatment sequencing, adjuvant imatinib duration, and management of rare GIST subtypes, used as the primary global clinical reference.
Imatinib mesylate in advanced gastrointestinal stromal tumors
The Lancet (2002)
Early pivotal European phase II trial demonstrating major response rates and disease control with imatinib in advanced GIST, establishing targeted kinase inhibition as a transformative treatment approach in solid tumors.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 保罗·卡萨利 的研究动态
Follow Paolo G. Casali's research updates
留下邮箱，当我们发布与 Paolo G. Casali（Fondazione IRCCS Istituto Nazionale dei Tumori, Milan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment